Cases & Deals

BioMarin expands global patent portfolio related to KUVAN

Clients BioMarin Pharmaceutical, Inc.

Jones Day advised BioMarin Pharmaceutical, Inc. in the expansion of a global patent portfolio relating to KUVAN (sapropterin dihydrochloride), which is indicated for the treatment of hyperphenylalaninemia due to tetrahydrobiopterin-responsive phenylketonuria (PKU).